Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab versus mepolizumab in relapsing or refractory EGPA
MOH_2019-09-26_007418Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Benralizumab with Mepolizumab (2 arms). Started Aug 2019; status: active, not recruiting.
02
Drugs
benralizumabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on MOH_2019-09-26_007418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-26_007418.